GlassScriptPhysician profile
Casey Moore Lowrey
NPI 1831623891
$4,490.28
in general payments reported to CMS, 2019-2025
23 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 90% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $462 · 2023: $1,052 · 2024: $1,506 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $818.43 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $395.62 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $364.84 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $327.49 | 2023-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $323.23 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $269.58 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $266.94 | 2022-2025 | Spravato |
| Alkermes, INC. | $235.78 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $226.28 | 2024-2025 | |
| Tris Pharma INC | $215.35 | 2023-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $214.45 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $136.27 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $112.83 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $103.21 | 2022-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $98.39 | 2023-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $92.93 | 2024 | |
| Collegium Pharmaceutical, INC. | $72.02 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $67.10 | 2023 | Ingrezza |
| Neos Therapeutics, LP | $47.05 | 2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $40.16 | 2024-2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $33.55 | 2025 | Relexxii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.89 | 2025 | |
| Noven Therapeutics, LLC | $13.89 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Lowrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.